Beyond Chemotherapy: Network Meta‐Analysis Reveals Optimal Neoadjuvant Strategies for Luminal Breast Cancer
NET is a viable alternative to NCT in HR+/HER2- patients. CDK4/6 + ET demonstrates superior tumor reduction and safety, potentially enabling postoperative therapy de-escalation. These findings support NET as a strategic option for optimizing outcomes while minimizing toxicity.
Authors
- Tao Huang (ORCID: https://orcid.org/0000-0002-7086-570X)
- Peixin Du (ORCID: https://orcid.org/0000-0002-8393-0726)
- Xinyu Li (ORCID: https://orcid.org/0000-0001-8573-5476)
Institutions
- Ningxia Medical University (CN)
- Wuhan Union Hospital (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cam4.71648
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00